3 tips for AI researchers studying palliative care

Machine learning (ML) can provide significant value in the field of palliative care. However, according to a thorough analysis published in HRB Open Research, researchers still have a lot of unexplored ground to cover before the technology reaches its full potential.

“ML is a subset of artificial intelligence that is rapidly advancing capacity to identify patterns and make predictions using large datasets,” wrote Virginia Storick, Trinity College Dublin in Ireland, and colleagues. “In contrast to traditional analytic methods, where the analyst specifies data inputs according to hypotheses and/or conceptual models, ML approaches leverage computing power to identify patterns in available data and can make inferences without explicit user instruction.”

To see how researchers were exploring ML technology, Storick et al. analyzed seven databases for peer-reviewed studies of how it can improve palliative care for adults. The specific outcomes they looked for were survival, quality of life (QoL), place of death, costs and receiving “high-intensity treatment” near the end of life.

Ultimately, the team explored three studies that examined ML and palliative care. The first study involved predicting six-month mortality, the second involved predicting 12-month mortality and the third involved cross-referencing 12-month mortality with healthcare costs.

These are three key concerns the authors expressed about the current state of machine learning-based palliative care research:

1. Explore a variety of patient outcomes

“No included study examined patient outcomes such as QoL,” the authors wrote. “Evaluations of QoL are not straightforward because the outcome of interest is an individual and subjective concept where mortality is an observable binary state. Nevertheless, the reality is that living and dying with serious illness, and caring for those populations, is messy and complex. Studies characterizing palliative care need beyond mortality, for example those at risk of pain or unmet need or death anxiety, and accurately predicting risk would have the capacity to improve clinical decision-making and treatment pathways.”

2. Include the perspective of caregivers

While the patient is always going to be the center of these studies, researchers should also consider the role of unpaid caregivers. The authors noted that evaluations of “dyad and family outcomes” are becoming more and more common in palliative care research—a trend that did not carry over into the ML-based literature they read.

“Identifying caregiver needs in advance would also have vast potential benefit,” they added.

3. Cover as much time as possible

Storick and colleagues noted that the studies all included a timeframe of six to 12 months. If more time was covered, the findings could potentially have a more lasting affect on patient care.

“Treatment choices from diagnosis have the greatest scope to impact outcomes and costs, and so studies that can inform these choices are the most useful,” they wrote.

Overall, the authors explained, ML has shown “the potential to support clinicians in improved decision-making” when it comes to palliative care for adult patients. But the research up to this point has been lacking in many areas.

“Applications of ML approaches to policy and practice remainsformative,” they concluded. “Derived results depend on available data and must be interpreted in this context. Future research must not only expand scope to consider other outcomes and longer timeframes, but also address individual needs and preferences in the context of prognosis, and engage with the profound ethical challenges of this emerging field.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.